Gesellschaft Fuer Epilepsieforschung

The laboratory concentrates on primary generalized tonic‑clonic seizures and related syndromes such as Dravet Syndrome and Lennox‑Gastaut Syndrome. The purpose of these studies is to evaluate new oral agents that can reduce seizure frequency and improve patients’ daily functioning.

• Evaluation of XEN1101 versus placebo for generalized seizures
• Assessment of BHV‑7000 as adjunctive therapy in idiopathic generalized epilepsy
• Study of Staccato alprazolam for rapid seizure termination
• Investigation of fenfluramine in patients with generalized seizure phenotypes

Gesellschaft Fuer Epilepsieforschung in Bielefeld conducts these trials within a dedicated neurology research facility.

Research at this site targets adult focal epilepsy, especially refractory forms that persist despite standard medication. The trials aim to test adjunctive therapies that can lower the number of focal seizures and provide better seizure control.

• XEN1101 as adjunctive treatment for focal‑onset seizures
• Vormatrigine versus placebo in adults with focal seizures
• Comparison of levetiracetam extended‑release and immediate‑release formulations
• PRAX‑628 efficacy in focal‑onset or primary generalized tonic‑clonic seizures

The Bielefeld facility supports these investigations with two experienced investigators and a commercial‑grade laboratory environment.

This centre focuses on rare conditions such as CDKL5 Deficiency disorder and broader Developmental and Epileptic Encephalopathies, including Dravet Syndrome. Trials are designed to explore disease‑specific therapies that can reduce severe motor seizures and enhance developmental outcomes.

• Fenfluramine (ZX008) efficacy in CDKL5 deficiency
• LP352 (bexicaserin) in Dravet Syndrome and DEE
• Zorevunersen (STK‑001) for major motor seizures in Dravet Syndrome
• Long‑term safety of fenfluramine in pediatric and adult DEE cohorts

The laboratory’s commitment to rare‑disease research positions it as a key hub for innovative epilepsy therapies in Europe.

A major research theme is rapid seizure termination, using approaches such as inhaled Staccato alprazolam. Studies also assess long‑term safety of acute treatments and adjunctive agents like soticlestat when combined with standard care.

• Rapid‑termination efficacy of Staccato alprazolam within 90 seconds
• Open‑label extension evaluating long‑term safety of Staccato alprazolam
• Soticlestat adjunctive therapy with ASMs, VNS, or ketogenic diet
• Comparative safety of acute seizure rescue medications

As a commercial research organization, the site integrates acute‑care objectives with broader epilepsy programs.

Investigations also address how different formulations and dose strengths influence efficacy, exemplified by studies of levetiracetam extended‑release versus immediate‑release, and multiple dose levels of BHV‑7000 and XEN1101.

• Levetiracetam XR vs IR in drug‑resistant focal seizures
• Low‑dose versus high‑dose BHV‑7000 efficacy in refractory focal epilepsy
• Dose‑response assessment of XEN1101 in focal seizure frequency
• Comparative safety of varying BHV‑7000 strengths in generalized epilepsy

These studies, led by two investigators, aim to fine‑tune therapeutic strategies for optimal seizure control.